GlassScriptPhysician profile
Isaac Zaki
NPI 1114211190
$4,865.82
in general payments reported to CMS, 2019-2025
29 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $538 · 2021: $670 · 2022: $769 · 2023: $913 · 2024: $1,109 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $778.65 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $569.62 | 2019-2025 | |
| Daiichi Sankyo INC. | $493.07 | 2020-2022 | |
| Exact Sciences Corporation | $423.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $390.80 | 2020-2025 | |
| Abbvie INC. | $290.47 | 2021-2025 | Linzess, Viberzi, Creon |
| Viiv Healthcare Company | $277.53 | 2022-2025 | Apretude |
| Janssen Pharmaceuticals, INC | $274.37 | 2020-2023 | Xarelto |
| Amgen INC. | $206.96 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $170.84 | 2020-2023 | Farxiga, Fasenra |
| Novo Nordisk INC | $169.26 | 2024-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $132.14 | 2024 | Voquezna |
| Cranial Technologies, INC | $108.43 | 2019-2021 | |
| Penumbra, INC. | $96.04 | 2023 | Red 72 |
| Lilly USA, LLC | $93.56 | 2022-2025 | Mounjaro, Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.10 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.82 | 2025 | Xifaxan |
| Allergan, INC. | $44.51 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $30.37 | 2022-2023 | Quviviq |
| Phadia US INC. | $27.33 | 2020-2021 | |
| Abbott Laboratories | $26.48 | 2023 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $25.23 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.22 | 2023 | Gvoke Hypopen |
| Mannkind Corporation | $15.91 | 2025 | |
| Dexcom, INC. | $15.76 | 2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $15.22 | 2019 | |
| Genentech USA, INC. | $15.00 | 2020 | |
| Janssen Biotech, INC. | $13.17 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Zaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.